Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma Meeting Abstract
| Authors: | Abou-Alfa, G. K.; Chan, S. L.; Kelley, K.; Lau, G.; Kudo, M.; Sukeepaisarnjaroen, W.; De Toni, E. N.; Furuse, J.; Kang, Y. K.; Galle, P. R.; Rimassa, L.; Heurgué, A.; Tam, V. C.; Dao, T. V.; Thungappa, S. C.; Breder, V.; Ostapenko, Y.; Reig, M.; Makowsky, M.; Gupta, C.; Negro, A.; Sangro, B. |
| Abstract Title: | Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma |
| Meeting Title: | Annual Meeting of the American Association for the Study of Liver Diseases (AASLD): The Liver Meeting |
| Journal Title: | Hepatology |
| Volume: | 78 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Nov 10-14 |
| Meeting Location: | Boston, MA |
| ISSN: | 0270-9139 |
| Publisher: | John Wiley & Sons |
| Date Published: | 2023-10-01 |
| Start Page: | S90 |
| End Page: | S91 |
| Language: | English |
| ACCESSION: | WOS:001094865400088 |
| PROVIDER: | wos |
| PUBMED: | 37820069 |
| DOI: | 10.1097/HEP.0000000000000580 |
| Notes: | Meeting Abstract: 87 -- Source: Wos |
